Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Norfloxacin penetration into human renal and prostatic tissues.

Literature DB >> 3834837

Norfloxacin penetration into human renal and prostatic tissues.

M G Bergeron, M Thabet, R Roy, C Lessard, P Foucault.

Abstract

Concurrent norfloxacin concentrations in serum, kidney, and prostatic tissue were determined in 14 patients. Mean ratios of norfloxacin concentration in tissue over concentration in serum were 6.6 +/- 2.8 for the kidney and 1.7 +/- 0.2 for the prostate samples. The levels were above the MICs of most urinary pathogens.

Entities: Chemical Species

Mesh：

Substances：
Norfloxacin

Year: 1985 PMID： 3834837 PMCID： PMC180245 DOI： 10.1128/AAC.28.2.349

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. Influence of single or multiple doses of gentamicin and netilmicin on their cortical, medullary, and papillary distribution.

Authors: M G Bergeron; S Trottier
Journal: Antimicrob Agents Chemother Date: 1979-05 Impact factor: 5.191

2. The pharmacokinetics and tissue penetration of norfloxacin.

Authors: Z N Adhami; R Wise; D Weston; B Crump
Journal: J Antimicrob Chemother Date: 1984-01 Impact factor: 5.790

3. A re-appraisal of treatment in chronic bacterial prostatitis.

Authors: W R Fair; D B Crane; N Schiller; W D Heston
Journal: J Urol Date: 1979-04 Impact factor: 7.450

4. Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance.

Authors: D Greenwood; M Osman; J Goodwin; W A Cowlishaw; R Slack
Journal: J Antimicrob Chemother Date: 1984-04 Impact factor: 5.790

5. Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.

Authors: G Panichi; A Pantosti; G P Testore
Journal: J Antimicrob Chemother Date: 1983-06 Impact factor: 5.790

6. Norfloxacin disposition after sequentially increasing oral doses.

Authors: B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal: Antimicrob Agents Chemother Date: 1983-02 Impact factor: 5.191

7. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections.

Authors: J Sabbaj; V L Hoagland; W J Shih
Journal: Antimicrob Agents Chemother Date: 1985-03 Impact factor: 5.191

8. Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.

Authors: E J Goldstein; M L Alpert; B P Ginsberg
Journal: Antimicrob Agents Chemother Date: 1985-03 Impact factor: 5.191

9. Antibacterial activity of norfloxacin.

Authors: S R Norrby; M Jonsson
Journal: Antimicrob Agents Chemother Date: 1983-01 Impact factor: 5.191

10. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

Authors: H C Neu; P Labthavikul
Journal: Antimicrob Agents Chemother Date: 1982-07 Impact factor: 5.191

12 in total

Norfloxacin penetration into human renal and prostatic tissues.

1. Influence of single or multiple doses of gentamicin and netilmicin on their cortical, medullary, and papillary distribution.

2. The pharmacokinetics and tissue penetration of norfloxacin.

3. A re-appraisal of treatment in chronic bacterial prostatitis.

4. Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance.

5. Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.

6. Norfloxacin disposition after sequentially increasing oral doses.

7. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections.

8. Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.

9. Antibacterial activity of norfloxacin.

10. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

1. Pharmacologic Basis for the Treatment of Pyelonephritis.

2. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.

Review 3. Quinolone antibacterial agents for the treatment of genitourinary tract infections.

4. A new method for assaying antimicrobials in the prostate.

5. Enoxacin penetration into human prostatic tissue.

6. Fleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids.

Review 7. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Review 8. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Review 9. Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Review 10. Fluoroquinolone antimicrobial agents.